[Establishment of an Onco-Ophthalmology Collaboration for Tisotumab Vedotin and Initial Experience with Ocular Adverse Events].

Abstract

Background: Tisotumab vedotin (TV), an antibody-drug conjugate targeting tissue factor (TF), was approved in Japan in 2025 for the treatment of recurrent/metastatic cervical cancer. As TF is also expressed on the ocular surface, TV frequently causes ocular adverse events (OAEs), necessitating strict management. This paper reports on the established'onco-ophthalmology'collaboration system developed to manage these risks.

Methods: A multidisciplinary protocol involving medical oncologists, ophthalmologists, pharmacists, and nurses was implemented. Key components included pre-treatment ophthalmic assessment, pharmacist-led guidance on prophylactic eye drops, cooling during treatment, and a rapid referral system upon symptom onset.

Results: Between June and October 2025, 5 patients received TV therapy. One case (20%) developed Grade 2 pseudomembranous conjunctivitis. Immediate ophthalmic evaluation revealed neutrophilic infiltration without infectious findings on smear examination. Symptoms resolved within 7 days of steroid treatment.

Conclusion: Whilst preventative measures are crucial, ocular complications remain possible. This case demonstrates that early diagnosis and effective management are achievable through the onco-ophthalmology liaison system, ensuring the safe continuation of TV therapy.